# Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

> **NCT02273726** · PHASE3 · COMPLETED · sponsor: **Kyntra Bio** · enrollment: 741 (actual)

## Conditions studied

- CKD Anemia in Stable Dialysis Patients

## Interventions

- **DRUG:** Epoetin Alfa
- **DRUG:** Roxadustat

## Key facts

- **NCT ID:** NCT02273726
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-15
- **Primary completion:** 2018-09-19
- **Final completion:** 2018-09-19
- **Target enrollment:** 741 (ACTUAL)
- **Last updated:** 2021-10-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02273726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02273726, "Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02273726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*